BridgeBio Pharma (BBIO) Share-based Compensation (2018 - 2026)

BridgeBio Pharma has reported Share-based Compensation for 9 years, with the latest figure at $4.1 million in Q1 2026.

• Quarterly Share-based Compensation fell 84.26% year-over-year to $4.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$11.1 million (down 114.62% YoY) and the FY2025 annual result came in at $14.2 million, down 35.92% from the prior year.
• Share-based Compensation improved to $4.1 million in Q1 2026 per BBIO's latest filing, from -$84.2 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $37.3 million in Q2 2025 and troughed at -$84.2 million in Q4 2025.
• A 5-year average of $9.8 million and a median of $18.7 million in 2022 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2024 and 2025: Share-based Compensation surged 18078.81% in 2024, then plunged 6094.23% in 2025.
• Over 5 years, Share-based Compensation stood at $22.6 million in 2022, then jumped by 36.5% to $30.8 million in 2023, then sank by 95.45% to $1.4 million in 2024, then slumped by 6094.23% to -$84.2 million in 2025, then soared by 104.84% to $4.1 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $4.1 million, -$84.2 million, and $31.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.